First Know Thyself - A Self-Assessment Program on Management of Atopic Dermatitis​ and Improving Patient Outcomes

Allergy/ Immunology
Curriculum:
A Self-Assessment Program on Managing Atopic Dermatitis​ and Improving Patient Outcomes
Credits:
1.25 AMA PRA Category 1 Credit(s)™
Launch Date:
08-Dec-16
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Physicians, nurse practitioners, and physician assistants who specialize in allergy/immunology and dermatology

Relevant Terms:

Atopic Dermatitis

Bradley E. Chipps, MD

Bradley E. Chipps, MD
Medical Director, Respiratory Therapy and the Cystic Fibrosis Center
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA

Bradley E. Chipps, MD, is the medical director of Respiratory Therapy and the Cystic Fibrosis Center at Sutter Medical Center in Sacramento, California. He is also the associate medical director of the Sutter Community Hospitals Sleep Laboratory, which he established in 1984. Dr. Chipps has been in private practice in Sacramento since 1979. He is board certified in pediatric pulmonology and allergy and clinical immunology. He is the vice president of the American College of Allergy, Asthma & Immunology.
 
Dr. Chipps received his medical degree from the University of Texas Medical Branch in Galveston in 1972. He was a pediatric resident for two years before serving in the Air Force at Ellsworth Air Force Base in South Dakota for two years as a general pediatrician. He then completed a combined allergy and pulmonary fellowship at Johns Hopkins and spent one year on the faculty in the Pediatric Respiratory Sciences Division.
 
 
 

Lawrence F. Eichenfield, MD

Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
Chief, Pediatric and Adolescent Dermatology
University of California, San Diego School of Medicine
San Diego, CA

Lawrence F. Eichenfield, MD, is chief of pediatric and adolescent dermatology at Rady Children’s Hospital–San Diego, vice chair of the Department of Dermatology, and professor of dermatology and pediatrics at the University of California, San Diego (UCSD) School of Medicine.
 
Dr. Eichenfield received his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and chief resident at Children’s Hospital of Philadelphia, and completed his dermatology residency at the Hospital of the University of Pennsylvania.
 
Dr. Eichenfield’s clinical interests include atopic dermatitis, acne, psoriasis, vascular lesions including port wine stains and hemangiomas, neonatal dermatology, laser surgery, nevi, and skin signs of systemic disease. He has authored more than 300 journal articles, chapters, abstracts, and books on these topics and has served as the senior editor of Neonatal and Infant Dermatology. He has been published by Elsevier as well as The Eczemas and by Summit Communications. He is also editor-in-chief of Pediatric Dermatology and serves on the editorial boards of multiple journals and periodicals.
 
Dr. Eichenfield has been honored as a member of the Alpha Omega Alpha Medical Honor Society during medical school, as a recipient of the Benjamin Ritter Award at Children’s Hospital of Philadelphia, and as a recipient of excellence in teaching awards from UCSD Pediatrics, UCSD Dermatology, and Rady Children’s Hospital–San Diego. He has been named one of the “Best Doctors in America” since 1994. Dr. Eichenfield is past president of the Society for Pediatric Dermatology, past board member of the American Academy of Dermatology, and chair for the 69th Annual Meeting of the American Academy of Dermatology. Dr. Eichenfield is also a founding board member of the American Acne and Rosacea Society. He is a founder and co-chair of the Pediatric Dermatology Research Alliance (PeDRA).
1. Describe the pathogenesis of atopic dermatitis (AD) and the "atopic march" and discuss how the underlying pathology of the disease can be used to direct therapy
2. Utilize current therapies and describe how to utilize emerging treatments for AD based on safety and efficacy data, pathophysiology, guidelines, individual patient needs, and sustained efficacy, especially in patients with moderate-to-severe AD
3. Manage quality-of-life issues, psychosocial comorbidities, and treatment-related anxiety in patients with AD
4. Engage the patient as a partner in his or her care plan to ensure best treatment adherence and outcomes

PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
 
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Bradley E. Chipps, MD, has affiliations with AstraZeneca, Boehringer Ingelheim, Genentech, Meda, Merck, and Novartis (Consulting Fees; Fees for Non-CME/CE Services).
  • Lawrence F. Eichenfield, MD, has affiliations with Anacor/Pfizer, Genentech, Lilly, Otsuka/Medimetriks, Regeneron/Sanofi, TopMD, and Valeant (Consulting Fees); and Kimberly Clark and Regeneron/Sanofi (Investigator).
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
  • Amy Reeve has no affiliations with commercial interests to disclose
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Estimated time to complete: 1.25 hours
Medium: Internet
 
FEE INFORMATION
There is no fee for this educational activity.
 
COMMERCIAL SUPPORT
This activity is supported by an independent medical educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.
 
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above